This study elucidates a novel connection between aberrant mitochondrial dynamics, defective cell cycle regulation, and DNA damage in oncogenic processes occurring in vivo, suggesting that targeting mitochondrial fusion components may offer new therapeutic strategies to limit Yki/YAP-driven tumor growth. The gene discussed is YAP1; the disease is neoplasm.